Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Anika Therapeutics (NQ: ANIK )

16.97 -0.46 (-2.64%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 89,496
Open 17.54
Bid (Size) 15.95 (10)
Ask (Size) 18.15 (4)
Prev. Close 17.43
Today's Range 16.95 - 17.62
52wk Range 16.00 - 29.11
Shares Outstanding 14,828,456
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Anika To Participate in December 2024 Investor Conferences
From Anika Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga

Performance

YTD
-25.11%
-25.11%
1 Month
-30.85%
-30.85%
3 Month
-33.69%
-33.69%
6 Month
-30.93%
-30.93%
1 Year
-20.03%
-20.03%

More News

Read More
Anika Announces Strategic Update of Business with Sale of Arthrosurface and Plan to Divest Parcus Medical
From Anika Therapeutics Inc.
Via GlobeNewswire
What's Next: Anika Therapeutics's Earnings Preview
Via Benzinga
Anika Therapeutics: Q4 Earnings Insights
Via Benzinga
Earnings Outlook For Anika Therapeutics
Via Benzinga
Anika Announces Third Quarter 2024 Results Conference Call Date
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Anika Therapeutics Inc.
Via GlobeNewswire
Sidoti Events, LLC's Virtual August Micro-Cap Conference
Via ACCESSWIRE
ANIK Stock Earnings: Anika Therapeutics Beats EPS, Misses Revenue for Q2 2024
Via InvestorPlace
Anika to Participate in the Sidoti Virtual Investor Conference
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika to Issue Second Quarter 2024 Financial Results on Thursday, August 8, 2024
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika Announces Full Market Release of the Integrity™ Implant System, a Regenerative Hyaluronic Acid-Based Scaffold for Rotator Cuff and Other Tendon Repairs
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Anika Therapeutics Inc.
Via GlobeNewswire
Peeling Back The Layers: Exploring Anika Therapeutics Through Analyst Insights
Via Benzinga
Anika Enters into Cooperation Agreement with Caligan Partners
From Anika Therapeutics Inc.
Via GlobeNewswire
ANIK Stock Earnings: Anika Therapeutics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika to Issue First Quarter 2024 Financial Results on Wednesday, May 8, 2024
From Anika Therapeutics Inc.
Via GlobeNewswire
Anika to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Anika Therapeutics Inc.
Via GlobeNewswire
Earnings Scheduled For March 13, 2024
Via Benzinga
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Anika Therapeutics Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.